|1.||Akimoto, Jiro: 9 articles (08/2015 - 07/2008)|
|2.||Kato, Harubumi: 9 articles (09/2011 - 10/2003)|
|3.||Usuda, Jitsuo: 8 articles (02/2015 - 12/2007)|
|4.||Aizawa, Katsuo: 8 articles (05/2013 - 10/2003)|
|5.||Arai, Tsunenori: 7 articles (09/2015 - 12/2006)|
|6.||Ichinose, Shuji: 7 articles (02/2015 - 12/2007)|
|7.||Ikeda, Norihiko: 7 articles (02/2015 - 12/2007)|
|8.||Maehara, Sachio: 6 articles (02/2015 - 12/2007)|
|9.||Ohtani, Keishi: 6 articles (02/2015 - 12/2007)|
|10.||Okunaka, Tetsuya: 6 articles (09/2011 - 10/2003)|
07/01/2008 - "The results of the present study suggested the potential of NPe6 as a promising photosensitizer for use in PDD for accurate grasp of the extent of removal during the course of malignant glioma surgery."
01/01/2014 - "Our results suggested that type of glioma cell death in NPe6-PDT changed with fluctuations in laser and NPe6 dose, and that combination of 30 µg/mL NPe6 with 5 J/cm(2) laser is the best treatment condition for inducing an increase in apoptotic cells while keeping rate of necrotic cell death low in this in vitro study. "
06/01/2012 - "Preliminary clinical report on safety and efficacy of photodynamic therapy using talaporfin sodium for malignant gliomas."
05/01/2013 - "Photodynamic therapy with talaporfin sodium induces dose-dependent apoptotic cell death in human glioma cell lines."
09/01/2008 - "Photodynamic therapy of C6-implanted glioma cells in the rat brain employing second-generation photosensitizer talaporfin sodium."
03/01/2002 - "The results confirmed that a significantly greater amount of NPe6 was incorporated by human umbilical vein endothelial cells (HUV-EC1) and the cervical cancer cell lines than by human umbilical cord-derived fibroblasts. "
01/01/2010 - "Clinical and preclinical studies indicate that talaporfin sodium treatment may offer a powerful option to synergize current therapies, as well as an alternative monotherapy in treating cancer."
02/01/2005 - "Prior studies had shown that it is the level of NPe6 in the circulation that predicts for photodynamic efficacy, indicating vascular shut-down to be the predominant mode of tumor control. "
12/01/2004 - "In this study, the absorption spectrum of novel Au-NPe6 in the diagnosis of deeply sited tumors was investigated, and the results were compared with the parent photosensitizer NPe6. "
10/15/2003 - "A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors."
11/01/2012 - "Photodynamic therapy using talaporfin sodium (Laserphyrin®) for bile duct carcinoma: a preliminary clinical trial."
01/01/2000 - "Given intravenously, NPe6 at a dose of 5 mg/kg and excited with a 664-nm wavelength laser beam 6 hours later can define experimentally induced deep-seated esophageal carcinoma in rabbits, by using an endoscopic fluorescence imaging system."
05/01/2010 - "NPe6 PDT was effective in carcinomas even in the presence of bile, and causes no serious complication for the liver and Glisson structure. "
07/01/2007 - "No studies have been conducted of PDT using Npe6 (Npe6-mediated PDT), a second-generation photosensitizer, in the human oral carcinoma cell line, HSC-3 cells. "
05/01/2013 - "Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma."
|4.||Lung Neoplasms (Lung Cancer)
12/01/2007 - "PDT using NPe6 will become a standard option of treatments for centrally located early lung cancer."
12/01/2007 - "Photodynamic therapy (PDT) using Talaporfin is an attractive treatment for central-type early lung cancer. "
02/01/2010 - "The purpose of this study was to investigate the association between the expression of BCRP and the efficacy of PDT using Photofrin, or the second-generation photosensitizer, NPe6, for centrally located early lung cancers. "
09/01/2011 - "To select a photosensitizer for lung cancer treatment and to improve the efficacy of PDT, the mechanisms of action for PDT using Photofrin or NPe6 must be elucidated and the phenomena validated by analyzing molecular determinants from clinical samples. "
12/01/2007 - "Photodynamic therapy for lung cancers based on novel photodynamic diagnosis using talaporfin sodium (NPe6) and autofluorescence bronchoscopy."
|5.||Phototoxic Dermatitis (Phototoxicity)
01/01/2012 - "Talaporfin sodium is a rapidly cleared photosensitizer that is expected to have less phototoxicity. "
06/01/2008 - "In RASM, talaporfin sodium accumulated in lysosomes in vitro, and the phototoxicity to RASCs in vitro and to RASM grafted onto SCID mice in vivo depended on the concentration of talaporfin sodium and the laser energy. "
01/01/2015 - "The next generated talaporfin-sodium was used for PDT, in which phototoxicity was reduced and, however, the clinical efficacy for digestive tract malignancy has not yet been clarified. "
07/01/1998 - "Nevertheless, phototoxicity recovered when the concentration of NPe6 excessed the serum protein binding ability or there was free serum protein in the medium. "
07/01/1998 - "The protein-bound NPe6 cannot be uptaken by cells, thus there was no PDT phototoxicity. "
|2.||Talaporfin (talaporfin sodium)
|3.||Dihematoporphyrin Ether (Porfimer Sodium)
|7.||Photosensitizing Agents (Photosensitizers)
|9.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Photochemotherapy (Photodynamic Therapy)